ARNA - Earnings call transcript Q3 2021 | Arena Pharmaceuticals Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by, and welcome to the Arena Pharmaceuticals Third Quarter 2021 Update Conference Call. [Operator Instructions] I would now like to hand the conference over to your first speaker today, Vice President of Investor Relations and Corporate Communications, Patrick Malloy. Thank you. Please go ahead, sir.

Patrick Malloy

Great. good and Nika, you, afternoon, everyone. Thank for you joining us today. Thank results had We announcing review financial updates. a the you our key press XXXX afternoon to this chance hope program issued release QX and we

me I'll comments, hand regards and Executive will today's Executive to for President Vice then the the Joining Munshi, over and Chief call, Stelzer, with Chief few in on up who format opening are Officer; the Amit just today Financial our to Laurie President a along our open call make Officer. will moments, some to Q&A and a we Amit, call call the session. With

uncertainties I some uncertainties expectations, and plans, about we'll would begin, or the remind to beliefs, be timing we of pandemic. forward-looking you results, and that making today financial risks events including those that pipeline, projections COVID-XX and our Before statements future related goals, like risks our to involve

beyond which latest found certain involve disclosure available and statements Forward-looking obligation be documents. on we description information forward-looking A earnings of disclaim can are release to to press full be assumptions, All risks these currently Arena, statements. any our some our of forward-looking statements these based update in may and our risks control. SEC

call Now, I'd the like to Munshi. over Amit? Amit to turn

Amit Munshi

and and I everyone for thanks being release to chance on press Pat, Thanks, call the hope everyone a has review the today. got

Q&A. right let's So into jump

Operator

from question Your Instructions] [Operator of comes first line from Neena Okay. the Bitritto-Garg Citi.

Unidentified Analyst

Neena. [ph] This for on is Dina

on baseline in particular, to how characteristics the and be in Our That and compare the a additional you versus squeeze anti-androgen use share second severity baseline in first OASIS? OASIS, commentary would would for we details can and studies just they terms previous on can UC helpful. very question, be, disease any ELEVATE of maybe if the

Amit Munshi

Great.

study, we exception, Number XX disclosed XX%-XX%. running XX OASIS and had is overall who and naive ELEVATE similar very patients who about comments with just OASIS one we've is quick things of X in XX%-XX%, one, are to about So publicly. the XX% on pre-treated. running the are characteristics are XX% UC

in naturally but the they're won't So be same. range, both exactly the

patients So as XX is that's than ELEVATE more Other trial. robust. naive the notable everything the that, we in have difference only

Operator

comes line Alethia Fitzgerald. Your next question of from Cantor the from Young

Emily Bodnar

This in just on And from is read-through about your I studies thoughts the thoughts the in that quarter? the guess increase of Emily into I XQ would ELEVATE the UC for those second if that. Alethia. was confidence curious 'XX, out going data just readout on any positive, kind Crohn's come your around

Amit Munshi

will designs, UC that successful. separate Phase I of the in study size. are look, action keeping is our confidence XX-patient But Sure. III -- or perspective, X And there a large-scale is it X Crohn's separate disease caveats of mean, there mind again, in trial, very increases be study X-dose one Crohn's be placebo-controlled And will from are mechanism robust trial. diseases. no naturally a all a the

to confidence the the we up. go would our with naturally caveats of differences, expect So trial

Operator

Okay.

Your line next Partners. Guggenheim the question Yatin comes from from Suneja of

Yatin Suneja

that format into go I love we the just the Q&A. straight

Remicade, So question. treat-through facilitate the from a how using this obviously so a ozanimod? affect X One right? which comparison standard comparison you So the me. for design gold first is, with does of were trial But that's

is second regarding the placebo The rate.

to in the is placebo higher risk studies? reduce rate responses? the specifically rate, But rate in given XX% at the placebo XX% remission we placebo in low. the we And naive, have of XX% should are what both then to induction these to And have of seen to how patients embedded range. about the actually placebo that look phase, that studies the rate for be naive you XX% you patients, If for tend think

Amit Munshi

Thanks, Yes. Yatin.

take to back the So the first second first, let part. come me question we'll then and the

band comparative pretty our rates and placebo higher a all lower there. And across the OASIS consistent pre-treated that are across the are in of the patients. trials. that's in And the are out the trials, in between So most the naive narrow consistent placebo you're rates trials right,

rates So different we don't seeing anticipate placebo than being what's been dramatically historically.

If trial a I think, you ozanimod split. recall, the about was, XX%-XX%

XX%-XX% not a you're huge and see based is Ours at XX%-XX% split, historical variation least a to XX%-XX%, going evidence. on between

point think gives ulcerative important it that us used view the main the design, HUMIRA. discussion the And XX Remicade really For to clearer have. that's we both between of a you're products correct, much colitis, X and

when the we've also that of example ways real couple the some at importantly, disclose we There But how cross don't the in etrasimod re-randomize published as begin look up. have you so comparisons. And of can life to to most how responders. some as of a are you as We take a drugs some for world, discussed trial design your doing well and And will analyst chose data just do which a other it's the the are community we'll some backs methodologies, community importantly, work. to work historically. investor real that that there reasons, be

because of design the some to mimics trial the that design But is think across people study a we ThX do simply we'll treatment. superior real-world with kind So it caveats of arithmetic really out help comparisons. all

Operator

from line comes America. of question next Jason Gerberry from Your of the Bank

Chi Fong

this I trial on Chi one I first clinical X me on afternoon. for is guess This Jason. progression. for guess,

launch on will draw commercial there to progression? of any lymphopenia the across overall whether isn't enrollment early market of you has any new Derm a costs? guess, the and UC, is, can confirm Atopic ozanimod my any fluid I commentary with like Is you provide in physicians like on if clinical collection? Given you signals helpful? any if can Curious it remained seen for curious new or II can there's or everything Phase protocol of whatnot. etrasimod, question is variant that you've repeated guess COVID or read appetite second data whether And new I alarming terms opportunity what violation study the and be commentary if the in you management somewhat situation has trial SXP track an with any on or thoughts see

Amit Munshi

Chi. Thanks,

So commentary the from we no had in change quarters. terms study couple the remains over of of last conduct, Everything on-track.

of Our well below discontinuation interruptions, rates, dose our that all statistical is pre-planned expectations.

study we're pleased conduct the with So very board. across

days. As ozanimod far still is it's concerned, early as

pretty couple We have. the good things suggesting of boardings are for there's that inhibitors have a once-a-day and oral clearly looking a points appetite good the JAK data that without

I into reading the juncture. but super again, anybody seems also too early but pleased early. a is with read, early, with into remind in to this it's the been category, the at much But so encouraging. we're premium And early the and all caveats the that I'll products significant data again, ozanimod very, everybody it's very caution priced

couple points, know, now, cycle, more the while understand get some data patients. we'll going takes it also to we'll what's compounds I early exactly quarters think of broad from as in able available to have be that sure a they're make and to you a reimbursement of on. It's and coverage

become be commentary that. available? on again, monitoring additional so We'll points as provide to we'll data more this all continue tracking and And

Operator

Your Sachs. next Shibutani from question of Goldman from comes line Chris the

Chris Shibutani

questions. couple A of

and your we've your has know was the that regulatory the views issue of past Perhaps then in terms you JAKs. as a experiences there my take of seen you the at the about from standpoint, I'm TykX FDA you're the know with how if question. regulatory various lower approach? have that. thinking Bristol referenced a how mechanisms data disappointment. I'm was And your could that guide perceptions well some other that that address from surprising be your quarter, first to curious are and would own what curious and Over dose the drugs as a to

Amit Munshi

the and Sure, modalities Chris. variants look, Yes, the JAK development, other inhibitors. biologics TykX both mean, there's inhibitors, clinical including I then in of multiple

take a tremendous for is, monitoring a market does take and tremendous that effect, need one other there's for the oral black overall to-date. over we've that and got malignancies safe, not and without patients time monitoring seen events a It's box without of black once-a-day things durable thromboembolic a box. ongoing all Our

profile terms paradigm. gold end the the human confident of has etrasimod potentially position in the be remain where in up could to we it standard of So a

emphasize other biologic affect important. spot And the disease it's and able for a example. everybody here developed oral, the we disease really, the is a single we again, the once a of of questions with being navigating being its really and think inhibitors, point approaches the are day to I physiology because get we're pathology at oral, that in a and kind right sweet complex more is etrasimod. than cytokine So type many lot And remind around that cytokine single we'll of

that got hope confident replicate remain right II of Phase we So that coming in Phase we've profile the and III. out to

second what was sorry, And part the the of question?

Chris Shibutani

the And TykX...

Amit Munshi

X, on for time inhibitors, know Janus, it's continue in And pathway, about consistent low low-dose X.X I or some you you specificity whatever using have think said that JAKXX, going increase even our fairly biology talk we've a prognostications are TykX now. see the will X And or yeah, to dose of and quite very the this TykX, years the JAKX, JAK-STAT working been as or the to a terms that with JAK the using agent same we some on, we're on be they talking see still effect of the well, on X, a they'll for as the pathway. in going JAKX, going profile JAK-STAT spot side with The think, JAK agents profile. what's we've about whether guys been a TykX,where the

once very come terms agent fact liabilities the in has that treatment of opportunity oral the we the to of to the inhibitors disease. back JAK again, be day the So of without significant a

Operator

Okay.

the Your Howerton line Chris Jefferies. next comes question from from of

Chris Howerton

billion the sheet is significant you on finalized simple. trials. clinical pretty $X.X burn of you I have guess but cash the now, as mine pretty Obviously, balance

to do commercialize So cash sufficient etrasimod anticipate you assuming success? having

Amit Munshi

the Well, let me off to call. on hand CFO, our Laurie? Laurie, who's that

Laurie Stelzer

Yes.

been as million, given Phase can with AD the decline the of has and expect Phase And we some costs rolling the a in we burn the early haven't that builds. to burn, cash III would III there. off offset start guidance $XXX $XXX And million about UC by but quarter. commercial some be cash our that of So forward

over to little forward finalization cash the some that So a positive $XXX will cash be the the time. with million. we position feel good of guidance with hopefully, we UC And at data budget very give and about able

Chris Howerton

if that What Phenomenon. exactly? seeing you for for Amit, II little more don't Could Okay, And Raynaud's cool. Phase about may, that opportunity? remember tell the I is bit Temanogrel I just this a us before

Amit Munshi

Sure.

our multiple can even pathologies. you go a cardiovascular as agents phases terms different potential So have they X know, agents quite indications, of in our have few disease

states. disease various across conserved quite is biology know, all we As

So some of quite follow There's you this specifically, quite that major role secondary plays significant a there. systemic systemic prevalence to with serotonin secondary we sclerosis. were that striking biology. these systemic In this of believe it's a not can in so sclerosis. that XXX,XXX not patients, almost patients to condition, case, really we're And

pathology at that II spot already the quantitative II is in Phase in-house a In a already with on, another another measure indication outcome infrared So disease we to that's and Phase in compound that case, really in given here working that's using actually an progressing already can we're there's given interesting indication. this opportunity explore look you thermography, think nature.

continue that we the utility broad these of fantastic compounds So expand have. again, to

up study excited that we're it, we're running. excited about So and get and to

Operator

the line comes next Schwartz SVB Your from Joseph Leerink. of from question

Joseph Schwartz

the wondering each activity? distribution other, this or way and patients on in if if for can was enrolled patients disease or who And account XX any XX been differences into also could the UC? in direction how and skew clinicians us geographical give other I any compares behave insight the in have results of you in to studies ELEVATE based

Amit Munshi

Sure.

ways, Joe. So different I'd answer that X

is, really to move sites the from same one it's that the clinical other. study First

decade That's breakdown on that locally, our ever So data. very, that area. do this decades a in sites a Number to XX a clinical can endoscopies and example, lot only of the very on then day, if centrally are in we we XX, overlap you'd X Venn were clinical were two, of way lot that ago, in helps with and many clinical for sites. a the diagram, sites work so read the There's a get and noise read, able detailed see a ozanimod, substantial created number one. endoscopies and ago, heterogeneity, and back the for

is again, standardize, we to lot this back centralized decade to to geographic variability. a going eliminate readings plus, of then that So that move a endoscopy

Operator

of line Jessica from Morgan. the JP comes Fye question next from Your

Jessica Fye

to just the could safety second could put indication it efficacious think the just more an show is get but to then to in differentiated I of is you does clear Phase us of dose about was do likely learn maybe you from what truly different ozanimod? clear, on just more expect I you forward differently, question such looking etrasimod from And Two, what remind if these II? able to how talk other? you think move how result from basically make this efficacy hoping stronger specifically you up thinking can ahead end how study you is or do Crohn's, is think sub-study thought were -- which than with that you each to a

Amit Munshi

Yes.

I'll through just a We've go tool to SAR was a the have first medicinal the at the at these the libraries history same To of modulators work over got of we etrasimod. that way the everyone, a chemistry did everyone's on of etrasimod and did don't was in memory, program was refresh Arena. formal most done Scripps a receptor goes on that SXP decade. on compounds it some think not ozanimod done remind compound important the compounds. So part, back I

PX know we or to Derm has about, even cells, of a to And junctional differentiate affect and time So those has talking period from is, to whether It the continue efficacy effect. a something that with fantastic the that it Atopic UC that time. point one of lowest The been plays think and intrinsic of barrier closing via on diseases And SXP of and kinds we're And do role schedule, conditions. an we're axis, the the from SXPX begin chemistry dysfunction these example, would, historically. last multiple Number this more hits a And and we in rate the that it's barrier in on the does do over to VOC long things actually But role And profoundly know SXPX closing opens actually of titration against And that diseases. proteins fold. ability that the have our are this axis. sense. really we ozanimod in a published in work data, detail, barrier or to heart function. plays think, efficacy. well-known we'll we the we're only over SXPX perspective, that do to is implications all efficacy not was we exploring there in when those the really make we done functions. beneficiaries the got characterized these an the we've barriers, again, or is indication dendritic not for of the Crohn's literature in that opposite itself the hands and are

elucidate we're be dendritic this So to SXPX further. do is I very amount think doing as a to that cecaljunctional of that's very SXPX. with, communities an with the proteins scientific it on mentioned, major the the we're a we cleaner, thesis on going of even some contributor, to that significant it's activity a decade we cells, barrier that work a function. at think the Arena. is and of important And closing and intrigued through on activity to lot combination gone just continuing compound and rigorous work has do We fact chemistry over a that's medicinal The better think

It's really etrasimod or X IIa we As A don't as Crohn's Study days. at versus study far milligrams X looking milligrams in in early know. disease, Phase

explored lymphocyte to increase know X in mean about X in drives reductions X We milligrams compared a really haven't milligrams. that We XX% population. patient milligrams

linear a not step. So it's

X milligram, example, over XX%. drives X XX% X-X, X So about for and a about increase milligrams milligrams

dose. here. So don't translate Crohn's, how know higher that's makes we're clinic out hoping the The Crohn's to to that's we going heterogeneity to right what the Crohn's, and of severity of the in condition explore in the really find

Operator

line of the question MacKay Capital comes RBC next from Your from Kennen Markets.

Kennen MacKay

ELEVATE missed of potential the endpoint? or what to impact should you if as the instance, can the built wondering visits pandemic think relates ensuring patient help of trial Is COVID-XX comment some just on to of, us team This your doing. if sticking for the then And anything about there Maybe censoring was conceptualize could event. collection kind is work data potentially an to it make been wondering into trials, been up that, since from we the visits there? you've something I've about or I on UC KOL commercial thinking

you as of to to how expand the market sort Really, some much if trying with clinicians? can is again versus there what is bringing ozanimod of to in beyond wondering contextualize etrasimod etrasimod relates just this table Just your the really it doing UC? can what understand conversations is

Amit Munshi

Sure.

to study that attracting or trials, won't we're trial, our or expectations. with our So patients coming us in have off. keep Phase through know, you when has design you ELEVATE discontinuations these process these terms III in, the pandemic, very back as -- interruptions you to you starting in really guys dose of the of the patients expectations rates pre-planned statistical rigorous pleased terms that dropping pre-planned And below allowed those work

are we've the that really of not. that's things say not pleased what we forecasted to, to that time, pay really and attention which had we ahead I'm is metric So we are seen

So overall continued. study conduct has

their get the in the got every when every As site, I've their ensure to put every world of country in every process beginning place were could inputs, perform to statistical every right the paid in diary to hit, in active patients and at sites where of we very, a terms endoscopies. patient, were compliant of their and every were mentioned to our around pre-planned all manual patients of work at very the and we their and being That sure sure terms the that's in medications, expectations. the into pandemic pandemic, terms able before publicly, site was day, dropouts making went track hands-on the think I we of terms discontinuations and dividends endoscopy, making being visit that below their compliant endoscopies,

of one, commercialization the intrinsic the rate, readiness. X rate are of to the a absence our different, we think, dramatically think heart think faster titration of has terms sort ways, think schedule, I compound course, In I some there's different Number that levels effect. commercial about product, features on X the of much first dose lowest the a of

changes then most baseline, ozanimod important consistent in patients off notably, as the from a rate. has. seen what's our within are to sites the withdraw all back of and clinicians the LFT you research And haven't XXX% off When most by of the drug, for We week is quantitative label.

days wait ozanimod. another agent You introduce immunomodulatory have to XX to for after

So intrinsic those features we intrinsically that with different to then that etrasimod makes control. a have having think physicians and are level do of certain the very

will from that we of translate all will hope. eventual a the differentiated us foundation a give into ozanimod. So as And for label that product

it's So to is back Number group. over has and having one. We back a research, that's doing goes over. more and quantitative work data, two And over the we're study. this really these ever the Nobody It's landmark study. number patient moderate it study. again, peri-approval to the think coming studied points a that GLADIATOR with

today. have thousands disease, have data that advanced dramatically. that meet don't of line expect market the literally We We but There criteria hundreds expands of approval. active who are the post to patients agents think quite for

with things payer excitement not that piece in And adopted in of straight-up now. evidence groups, payers the tremendous the lot add final integrated uptake. exactly reside evaluate investigator are etrasimod. to data, a KOL the with understand payer time the in spending can marketplace. game-changer outside how chance understand help terms a they real-world cost the when terms the product these and think amount working we're lot is payer And leaving in disease with delivery of using data We We're intercede the payers we in pathway how to who is be study. We're community a I'll or an in whether about where them the vendor of systems of the and will understand structures, and they're of have in this costs

we ability dividends in pay So rapid of our the get in think to that uptake payer terms community. huge will

that's earlier of of infrastructure the do line had So these platforms size early, And you than having as having be all the building privilege success. into able do. a of know, we've our building commercial companies very out began traditionally commercial to sight out began balance early. sheet we towards most But We to very much that.

get us. drug. the just of great II to It's drug enough So but matters for most And approved, data. none it's the a actually Phase thing this have enough until that's important not patients to receive not

study had clinical and the And thinking couple with years the so with again, medical also years payers, KOLs doing we've working we're that work liaisons the sites of began science XX a with on over X with ground work back about over now. GLADIATOR for

I So get attention all and an understand data lot a because these investor Phase could don't later you from into substandard is today, if things on. run on don't But endpoint, the these that the of you make early, launches investments perspective. are focus III that

I sure in make order back we the have So of super-important work now getting done view to on past aim to the the really kind is make end. sure commercial target, that's point we're our from of success think

Operator

from of from Joseph next the line Needham & Your Company. question comes Stringer

Joseph Stringer

question XX. Our of A. on I XX understand number you sub-study the is increased Cultivate to patients from

at Just thoughts it. to on based not least to would in your allow go to here favorable you on would scenario your guess be level a any that assuming confidence directly there registrational design would be increase your which results, trial. wanted I

or patients of if further study. run additional For increase example, the need would an you number to

you to And results there. areata year, the cohorts next X data the one? scenarios in the second then that about Just include alopecia for of trying mg from think would half

Amit Munshi

Yes.

of well the discussed to see allow to upadacitinib and a We sufficient their we've the Crohn's, registrational Phase move a quality as approximately approximately clinical our think to XX there's database being in in to the to move signal fact of to patients. in program. size II UC for registrational us able there was trial. terms interactions. So and ozanimod the Naturally, top clinical meaningful a total that a be that study, regulators sufficient a that's before, of on that of But important signal will as see database safety a the in had GI regulatory data is clear patients study XX precedent

So alopecia Crohn's is more think that's really treat working If been areata Atopic precedence the treat at and to much just focus, of about off more as we disease ulcerative our did study, really. we than difficult AA X Derm, is milligrams, a disease again, colitis. a difficult than to

there. healthy. benefit only we to the in thought milligrams from milligrams in data Again, patient we so And group important was X add X any have don't risk

looking we'll looking study. Crohn's We'll first same at thing there. AA X then see the response the for a in And so be for And data dose milligrams. similarly, we're the

Operator

of line Jason from JMP question the Securities. from next Butler comes Your

Jason Butler

Dupixent. EoE, trial if to evolving give VOYAGE wondering also any given into I'm us you recent in just could you on also for update landscape data the an and severe treatment looking the VOYAGE? enroll Are on patients the perspectives

Amit Munshi

Yes.

Dupixent across but those I trials, has other fantastic whether drug, some is remind different cytokines similar we we've oral, agents. are of histology, do these what to lymphocytes. don't that simplicate game I'll not patient chronic a most antibody Also, seen changer. diseases. if disease pure able CDX-positive the Dupixent.And or We diseases accomplish you the eosinophils, T again, multiple we're unlike the be activity, just phase will the what ThX parts able active see to of agents think everybody effects accomplished, the once-a-day that's in on a we're There's of meaningful So to in makeup are And CDX-positive we're substantial of these just these diseases. it's know agents, you ThX hitting that see process. multiple ThX think

types multiple a dendritic see other we've those variety all histology. in human of as mast cells, cell of activity models against demonstrated as types, cell well You well as and cells including as

having So population again, be last all we that population patient the the today, we've we on consistent on of are could in following over everything think know think biology changer. we done most And these the And we're makeups decade. across oral game once-a-day work the based significant a based trials. a

Operator

Your the of Trucchio line next question Patrick from H.C. comes from Wainwright.

Unidentified Analyst

for Myself very, Patrick. Jason speaking [ph], quick And have I X questions. I'm very

is, from will before, the the or the question details would first could a be change, assuming to can second and NDA if next filing ELEVATE filed on need available? be GLADIATOR forward program? strategy strategy from supplemental And before if positive after the And question is, development you discuss data quarter? include is business GLADIATOR my a going NDA there how a all So for Arena's outcome my the program

Amit Munshi

Sure.

study peri-approval is GLADIATOR the So to it's approval. study, the designed readout after the

population label approval is at build in we won't business about closer have how as in leg The refresh, terms continue over make HS, So in have IBD, excited that as clinician conditions, we'll dermatologic decisions to a after potentially out and study. portfolio company, section for development, time. as well of pass the context for for as we'll The data go potentially stool study, the and and really that our of maybe NDA. supplemental some We're GLADIATOR the we community Therapeutics. the aggressive and the and the with the through NDA after patient the just approval. the to studies approval we adds that. PPP another as And GLADIATOR time. clinical very about that in experience that assess additional and to again, of include it after you would we as data of really to payers. think did until look the And recently That's well as the will for X designed that get But we we transaction we'll think see that we'll Aristea even we get opportunities know,

that We quality novel that have opportunities a important. the for the thought on the X We, emphasis years, to the put an wanted compounds a are before stable we things over BD the XXX very last biology. had our we getting programs of area And process. over of therapeutic chemistry. and really rigorous We quality

not we things we'll out that to we But about many are are just ELEVATE in data there's thinking So today over build-out there. pipeline be time. as of that continue rigorous those post our how as

Operator

comes of the question Hoang from next SMBC. Your from David line

David Hoang

thinking get Aristea from and should the when comments that wanted just PPP, might bit little first asset, our you on development data about you asset? any I indications the be path So which in with of expectations terms pursue other a on to in-licensed, of for of we the refreshed seeing asset, that other some

Amit Munshi

Sure.

So Phase looking compounds well more in terms And the has compounds right with at how disease. the done, characterized HS about Aristea which at we that patients IIb a medicinal in had job Again, we with of well Phase and they? business pedigree. been where a work come the indications there. are such both time as neutrophilic team chemistry originated IBD how chemistry, fantastic is us right really compound much finding AstraZeneca. to in approach That's have as the important potentially right development done that in the these from, in this IIa substantial, rigor an lot we're thinking PPP spend X of

Pat, And believe correct don't at point. so any this timing collaboration. of those wrong, I clinical disclosed milestones I'm And excited for extremely about if the we're me any but we've

Patrick Malloy

anything. Correct. disclosed No, have not we

Amit Munshi

X in provide of II forward portfolio the we look well clinical our terms will in but Phase another beyond of asset some But company, catalysts UC readouts readouts potentially in data also context to more and build both us we those opportunity, move data. in time, will the terms in of market like. terms continue to compounds, Having in key allows data indications when over terms as with of

Operator

of Your next question comes JonesTrading. from from the line Agrawal Prakhar

Prakhar Agrawal

the actually design produced and maintenance but on induction. in to on relative diverging HUMIRA Firstly, UC, the decreased treat-through maintenance HUMIRA increased in phase. Remicade placebo-adjusted in Remicade maintenance phase results versus the slightly remission clinical have basis induction, slightly a in

is include confirm Dupixent you refractory allowed Derm trial? do initiation for just follow-up, question trial track XX? patients as a therapies also, trial that Remicade rescue Phase the So by And III to whether right if year-end. the And HUMIRA trial, or secondly, and is can my for is you on in on the Phase treat-through III competitor be mono-therapy UC A still the whether plan trial

Amit Munshi

Yes.

a of Dupixent will X% only Dupixent to of market. the X% have small remember, So about proportion AD yes, -- penetrated we is

wouldn't we of back So initiate Dupixent the refractory in for Coming and anticipate first in lot the of patients on-track that to end study the by the seeing to year is of study part next a the patients treat-through enrolling year. design. study,

of not challenge cross-trial but and the think years separated this is I XX just comparisons might comparisons, temporarily. cross-trial comparisons be cross-trial by always

remember, have you So were a in biologics and resolve. demographics patient other to it with tremendous no take space. developed, that was there first when Remicade The the approved

a HUMIRA different naive had And slightly XXX% so they had situation. patients.

the So this by is challenge always temporarily. of especially across when decade separated comparisons, they're our a upwards

today's understanding on caution I'd its own so, comparisons patterns understand in I merits, is need those this take today and unmet And treatment where at in today's to any we patients. the and have making the you treatment paradigm point, data think

between higher of a has you drop-off effect. plays and we We treatment. that's the a at patients the That substantial We dose antibodies. far part of of a portion largely HUMIRA in double X a due intensity Remicade antibodies. either or As double has neutralizing know rate to neutralizing months, know in pretty X think And big substantial pretty HUMIRA know, also role. also

molecule, So you don't have with that. a small

time points, modalities, about structures, we talking get So as to more time this get data. spend different different we'll the different and

Operator

back There are questions at Patrick this to turn further over I'll Malloy. it no time.

Patrick Malloy

Great. everybody, us with of And call. the the year. next you after we'll on speaking forward to that, joining look you, for first Well, today's with thank

very the much, rest everybody, thanks of day. the enjoy and So

Operator

Thank concludes This you participating. conference for call. today's

You may now disconnect.

Arena Pharmaceuticals (ARNA) 5 Nov 212021 Q3 Earnings call transcript